^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PRGN-2009

    i
    Other names: PRGN-2009, Adenoverse cancer vaccine
    Associations

    News

    Trials
    Company:
    Precigen
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    2ms
    Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer (clinicaltrials.gov)
    P2, N=16, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | N=29 --> 16 | Trial completion date: Nov 2028 --> Jul 2030 | Trial primary completion date: Nov 2025 --> May 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • PRGN-2009
    9ms
    PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancer. (PubMed, Cancer Immunol Immunother)
    PRGN-2009 was well tolerated, and immune responses were observed to PRGN-2009. Encouraging anti-tumor activity and OS were noted in the combination with BA arm, consisting mainly of checkpoint-resistant patients. Trial Registration ClinicalTrials.gov Identifier: NCT04432597.
    Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    bintrafusp alfa (M7824) • PRGN-2009
    1year
    Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer (clinicaltrials.gov)
    P2, N=29, Recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2027 --> Nov 2028 | Trial primary completion date: Nov 2024 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • PRGN-2009
    1year
    PRGN-2009-201: PRGN-2009 in Combination with Pembrolizumab Versus Pembrolizumab in Patients with Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P2, N=46, Recruiting, Precigen, Inc | Initiation date: Aug 2024 --> Nov 2024
    Trial initiation date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • PRGN-2009
    almost2years
    PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P2, N=46, Recruiting, Precigen, Inc | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • PRGN-2009
    almost2years
    Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer (clinicaltrials.gov)
    P2, N=70, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial • Combination therapy
    |
    cisplatin • docetaxel • PRGN-2009
    2years
    PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P2, N=46, Not yet recruiting, Precigen, Inc
    New P2 trial
    |
    Keytruda (pembrolizumab) • PRGN-2009
    2years
    20-C-0104: HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers (clinicaltrials.gov)
    P1/2, N=39, Active, not recruiting, National Cancer Institute (NCI) | N=20 --> 39 | Trial completion date: Oct 2023 --> Nov 2025
    Enrollment change • Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    bintrafusp alfa (M7824) • PRGN-2009
    2years
    Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer (clinicaltrials.gov)
    P2, N=29, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • PRGN-2009
    over2years
    Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer (clinicaltrials.gov)
    P2, N=29, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • PRGN-2009
    over2years
    20-C-0104: HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers (clinicaltrials.gov)
    P1/2, N=20, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Oct 2023 --> Nov 2022
    Trial primary completion date • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    bintrafusp alfa (M7824) • PRGN-2009
    over2years
    20-C-0104: HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers (clinicaltrials.gov)
    P1/2, N=20, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | N=76 --> 20
    Enrollment closed • Enrollment change • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    bintrafusp alfa (M7824) • PRGN-2009